--(BUSINESS WIRE)-- Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan ... lung disease (ILD) and pneumonitis, including fatal ...

--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was ...

The oral HER2 inhibitor zongertinib benefited patients with previously treated, HER2-mutated non-small cell lung cancer in a phase I clinical trial, according to results presented by John V. Heymach, ...

The green light from the European Commission means that Enhertu (trastuzumab deruxtecan ... risk of interstitial lung disease (ILD) and pneumonitis with AZ and Daiichi Sankyo's drug.

Perivascular niche-resident alveolar macrophages confer interstitial pneumonitis related to trastuzumab deruxtecan [abstract]. In: Proceedings of the American Association for Cancer Research Annual ...

2Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer, Zhejiang Cancer Hospital, Hangzhou, China. 3Zhejiang Key Lab of Prevention, Diagnosis and Therapy of Upper ...

This article includes detailed information about drugs approved by the FDA for oncology indications in 2025. The US Food and Drug Administration (FDA) has approved drugs for a range of oncology ...